chromosome 12 open reading frame 57Genealiases: C10 · GRCC10
Q-omics provides the consensus-scored C12orf57 profile across patient tissues and cancer cell-line models. C12orf57 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, C12orf57 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, C12orf57 protein abundance shows 28,679 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where C12orf57 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C12orf57 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C12orf57 survival associations across molecular data types. C12orf57 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C12orf57 RNA expression–survival associations across cancer types. High C12orf57 expression shows unfavorable associations in ACC, UVM, KIRP, UCS and DLBC, but favorable associations in PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for C12orf57 RNA expression.
This table summarizes C12orf57 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C12orf57. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C12orf57 shows lower tumor expression in KICH and UCEC and higher tumor expression in KIRC, LIHC, CHOL and KIRP. The KIRC box plot shows higher C12orf57 RNA expression in tumor versus normal tissue (log2 FC = +0.689, t-test p < 0.001).
This table shows molecular features associated with C12orf57 in patient tissues and cancer cell lines. In patient samples, C12orf57 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, C12orf57 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
